Ural, Kerem; Ulutas, Bülent

Mepyramine maleate treatment of urticaria in horses; a multi-centered, randomized, placebo controlled, double blinded clinical trial


Universidad del Zulia
Maracaibo, Venezuela

Available in: http://www.redalyc.org/articulo.oa?id=95916207007
MEPYRAMINE MALEATE TREATMENT OF URTICARIA IN HORSES;  
A MULTI-CENTERED, RANDOMIZED, PLACEBO CONTROLLED,  
DOUBLE BLINDED CLINICAL TRIAL

Maleato de mepiramina como tratamiento de la urticaria en caballos;  
un estudio multicéntrico, aleatorizado y controlado con placebo a doble ciego

Kerem Ural and Bülent Ulutas  
Department of Internal Medicine, Faculty of Veterinary, University of Adnan Menderes, Aydin-Turkey.  
E-mail: uralkerem@gmail.com

ABSTRACT

The aim of the present study was to investigate the efficacy of mepyramine maleate in horses with urticaria. A total of 31 horses, between the ages of 1 and 8 years, were enrolled and randomly assigned to either a placebo or an intramuscular mepyramine maleate group. Clinical evaluations were done by the same investigator, who scored clinical healing, throughout the study and was blinded to the allocation to the groups. At the end of the trial, mepyramine maleate treatment significantly decreased (P<0.001) the investigator’s clinical scores and while weak changes were detected in the placebo treatment group. In all of the horses treated, the lesions improved gradually within 6 hours after treatment. Complete clinical remission was detected within 6 to 18 hours and all treated horses completely cured within 24 hours of starting treatment. Urticaria was still evident in 8 out of 14 untreated control horses throughout the study. No recurrence was observed in treated horses within 1 week after therapy. Results of the present study indicate that mepyramine maleate may be a safe and effective therapy for horses with urticaria.

Key words: Urticaria, horse, treatment, mepyramine maleate.

INTRODUCTION

Urticaria, a common dermatological disorder [15], occur in horses (Equus caballus) of all ages [8, 13]. Although the pathophysiological mechanisms of urticaria is not very well defined in horses [6], it is characterized by dermal edema, with or without accompanying perivascular to diffuse infiltration including eosinophil and lymphocyte [12, 15], resulting from the mast cell degranulation and inflammation of the chemical mediators [15]. Urticaria may have immunological and nonimmunological background [15]. Urticaria has been suggested to be a cutaneous reaction [11] as a result of multivariable causes; mimicking reports in human being [1, 17], such as immunological basis involving hypersensitivity, allergic urticaria (ie. insect bite, drug eruption, atopy and food allergy) [5-8, 15]. Nonimmunological causes include cold urticaria, exercise induced urticaria and dermatographism (ie. pressure urticaria) [15].
Clinical appearance of equine urticaria presents as wheals, with acute to peracute onset, developing within minutes to hours [15], distributed bilateral and symmetrical on the trunk, neck, thorax, abdomen and extremities [8, 15]. Other rare clinical signs involve papule, giant (up to 20-40 cm diametered) or exudative wheals and gyrate/polycyclic forms [8, 15].

Clinical management of urticaria involves food elimination, intradermal skin testing and if necessary, subsequent hyposensitization therapy, and administration of corticosteroids and antihistamines. Another important point of clinical management is environmental modifications, for example, moving the horse to another location, eliminating sources of molds, removing stagnant water and stabilizing the horse in times when insects are known to be feeding. To the present author’s knowledge, intradermal testing has not been commonly used in equine practice in Turkey. Corticosteroid treatment (i.e., prednisolone and dexamethasone) is commonly effective for controlling urticaria occurring as a result of atopy, indeed they may cause serious side effects such as laminitis, steroid induced hepatopathy and iatrogenic hyperadrenocorticism [4, 14].

Antihistamines such as hydroxyzine pamoate and doxepin hydrochloride may be used in horses with urticaria [16]. However hydroxyzine and doxepin, may both cause side effects as drowsiness and nervousness in horses [16], resulting with challenging owner compliance. Therefore, a safely used and reasonably priced antihistamine that could be used for relieving urticaria would be of significant benefit to increase owner compliance.

The first-generation antihistamines are commonly prescribed drugs relieving allergic reactions and urticaria. Mepyramine is a first generation antihistamine, blocking the peripheral histamine H1 receptor [9]. It has been reported to cure hypersensitization in lambs (Ovis aries) [12], acute respiratory distress in cows (Bos taurus) [3] and to prevent nausea and vomiting induced by xylazine in dogs (Canis lupus familiaris) [2]. It is commercially available in Turkey in the veterinary market. The purpose of this study was to evaluate the efficacy of mepyramine maleate for the treatment of equine urticaria in a multi-centered, randomized, placebo controlled, double blinded clinical trial.

**MATERIAL AND METHODS**

**Study design**

Multicentered, randomized, placebo-controlled, double blinded clinical trial.

**Animals**

A total of 31 horses with history of conventional urticaria confined to different body parts were enrolled in the present study. The horses ranged in age from 1 to 11 years. There were 17 mares, 8 stallions and 6 geldings. Breeds represented included: 6 Thoroughbred, 5 Arabian, 5 Akhal Teke, 4 Dutch Warmblood, 4 Ponies, 3 Holsteiner and 1 of each of the following breeds: Selle Francais, Belgian Warmblood, Fresien and unknown breed.

**Allocation to treatment and owners’ evaluation**

Horses were randomized by coin toss, in that the side of the coin (heads=control, tails= treatment) determined the assignment of each horse. Once enrolled, horses were randomly allocated into two groups. Both owners and the investigator were blinded regarding the allocation to groups. One group, consisting of 17 horses, received intramuscular mepyramine maleate* administration at a dosage of 2mg/kg twice at 12 hours intervals, while the other group, consisting 14 horses, received the placebo containing purified water (at equivalent doses of mepyramine maleate).

**Investigator’s evaluation of clinical lesions**

At the beginning and at the end of the trial (hours 0, 6, 12, 18 and 24) clinical lesions were scored by the same investigator using a scale from 0 to 3 (0 being absent, 3 being severe) (TABLE I). The used scoring system was consistently applied to all the test subjects. Clinical lesions subject to evaluation included alopecia, scaling and crusting. Areas Evaluated included head, neck, shoulder, thorax, ventral abdomen and/or whole body. The total score of each horse was the sum of the scores assigned to each clinical signs. Therefore the total score for each horse was derived from the sum of the scores of alopecia, scaling and crusting and each horse was assessed on the same lesion on every examination. Briefly the scores were averaged for each horse [i.e. if a horse had 2 areas evaluated on the nearside and only 1 on the off side, these were added and divided by 3 (2+1)] to give the horse its score for that day examination. Mean and standard deviations of score lesions regarding the mepyramine maleate group and the placebo was shown (FIG. 1). The lesion scoring was carried out by an investigator blinded to the treatment the horses had received. The signs of resolution and therefore the improvement in clinical signs associated with urticaria were scored by the same investigator. In addition throughout the study, all horses were checked daily for evidence of adverse reactions to treatment. Besides clinical follow-up was further carried out for 1 months for evaluation of possible recurrence.

Clinical recovery was deemed the resolution of dermatologic changes related to urticaria. Cure was defined when all clinico-dermatological lesions were resolved.

**Statistical analysis**

Differences in the clinical score between the treatment group and the untreated placebo control group on the examination days were assessed by Mann-Whitney U test. Differences in the clinical score changes within-subject factor of time were analyzed using Wilcoxon test [10].
RESULTS AND DISCUSSION

Clinical signs and culture results

Among 31 horses examined, all had clinical lesions of urticaria. Accompanying skin lesions of urticarial horses were variable (TABLE II). They often exhibited conventional forms of urticaria (24/31), and in addition giant/exudative (4/31) or polycyclic (gyrate) forms of wheals (3/31) (FIG. 2) were observed. Other less common signs included scales (14/31), crusts (9/31), papules (8/31) (FIG. 4), alopecia (12/31) and oozing (4/31). The thorax (8/31), neck (7/31), and extremities (5/31) were most commonly involved. All affected animals had normal temperature, pulse and respiration. Other body systems were also normal.

In all of the horses treated, the lesions improved gradually within 6 hours after treatment. Complete clinical remission was detected within 6 to 18 hours and all treated horses completely cured within 24 hours of starting treatment (FIGS. 3 and 5). Urticaria was still evident in 8 out of 14 untreated control horses throughout the study. No recurrency was observed in treated horses within 1 week after therapy. No adverse post-treatment reaction was observed in any of the treated animals. Further follow-up was available for 1 months duration, with no recurrency.

TABLE I

<table>
<thead>
<tr>
<th>Groups</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hour_0</td>
<td>3</td>
</tr>
<tr>
<td>Hour_6</td>
<td>2</td>
</tr>
<tr>
<td>Day_12</td>
<td>1</td>
</tr>
<tr>
<td>Day_18</td>
<td>0</td>
</tr>
<tr>
<td>Hour_24</td>
<td>0</td>
</tr>
<tr>
<td>Treatment (n=17)</td>
<td>11</td>
</tr>
<tr>
<td>Placebo control (n=14)</td>
<td>9</td>
</tr>
</tbody>
</table>

Investigator’s clinical scores (FIG. 1)

As a function of time, mepyramine maleate treated group showed significant improvement in scores from hour 6 to hours 24, while the placebo group showed weak changes in scores. Comparison of the two groups revealed that the clinical scores did not differ between the groups on hour 0, whereas the treatment group showed a significantly lower clinical score than placebo group on from hour 6 and 12 (P<0.05) to hours 18 and 24 (P<0.001). *INDICATES AT THE TIME AT WHICH GROUPS WERE SIGNIFICANTLY DIFFERENT. * P<0.05, ** P<0.001 / RESULTADOS CLÍNICOS INVESTIGADOS EN HORAS 6; 12; 18 Y 24. DIECISIETE CABALLOS SE INCLUYERON EN EL GRUPO DE MALEATO DE MEPIRAMINA Y CATORCE EN EL GRUPO PLACEBO. COMPARACIÓN DE LOS DOS GRUPOS PUSO DE MANIFIESTO QUE LOS RESULTADOS CLÍNICOS NO FUERON DIFERENTES ENTRE LOS GRUPOS EN LAS HORAS 0, MIENTRAS QUE EL GRUPO DE TRATAMIENTO MOSTRÓ UNA PUNTUACIÓN CLÍNICA SIGNIFICATIVAMENTE INFERIOR AL GRUPO PLACEBO EN LAS HORAS DE 6 Y 12 (P<0.05) A LAS HORAS 18 Y 24 (P<0.001). * INDICA EN EL MOMENTO EN QUE GRUPOS FUERON SIGNIFICATIVAMENTE DIFERENTES. * P<0.05, ** P<0.001.

RESULTS AND DISCUSSION

Clinical signs and culture results

Among 31 horses examined, all had clinical lesions of urticaria. Accompanying skin lesions of urticarial horses were variable
TABLE II

CLINICAL BACKGROUND FOR HORSES WITH URTICARIA. N, NUMBER OF HORSES WITH THE CLINICAL SIGNS COMPARED TO THE TOTAL NUMBER OF HORSES.

<table>
<thead>
<tr>
<th>Sign</th>
<th>N</th>
<th>%</th>
<th>Duration of clinical signs</th>
<th>N</th>
<th>%</th>
<th>Localization of lesions</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wheals</td>
<td>31/31</td>
<td>100</td>
<td>&lt; 1 week</td>
<td>11/31</td>
<td>35</td>
<td>Whole body</td>
<td>3/31</td>
<td>9</td>
</tr>
<tr>
<td>-conventional</td>
<td>24/31</td>
<td>77</td>
<td></td>
<td></td>
<td></td>
<td>Head</td>
<td>3/31</td>
<td>9</td>
</tr>
<tr>
<td>-giant/exudative</td>
<td>4/31</td>
<td>12</td>
<td></td>
<td></td>
<td></td>
<td>Neck</td>
<td>7/31</td>
<td>22</td>
</tr>
<tr>
<td>-polycyclic (gyrate)</td>
<td>3/31</td>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td>Shoulder</td>
<td>3/31</td>
<td>9</td>
</tr>
<tr>
<td>Scales</td>
<td>14/31</td>
<td>45</td>
<td>&gt;4 weeks</td>
<td>9/31</td>
<td>29</td>
<td>Extremities</td>
<td>5/31</td>
<td>16</td>
</tr>
<tr>
<td>Crusts</td>
<td>9/31</td>
<td>29</td>
<td>recurring</td>
<td>4/31</td>
<td>12</td>
<td>Thorax</td>
<td>8/31</td>
<td>25</td>
</tr>
<tr>
<td>Papules</td>
<td>8/31</td>
<td>25</td>
<td>&gt;4 weeks</td>
<td>5/31</td>
<td>16</td>
<td>Abdomen</td>
<td>2/31</td>
<td>6</td>
</tr>
<tr>
<td>Alopecia</td>
<td>12/31</td>
<td>38</td>
<td>&gt;4 weeks</td>
<td>7/31</td>
<td>22</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oozing</td>
<td>4/31</td>
<td>12</td>
<td>1-4 weeks</td>
<td>3/31</td>
<td>9</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FIGURE 2. URTICARIAL WHEALS LOCATED ON THE HEAD.

FIGURE 3. SAME HORSE SHOWN IN FIG. 2, 24 HOURS AFTER INITIAL TREATMENT. NOTICE CLINICAL HEALING AND DISAPPEARANCE OF WHEALS.

FIGURE 4. MULTIPLE WHEALS LOCATED ESPECIALLY ON THE THORAX, BEFORE TREATMENT.

FIGURE 5. SAME HORSE SHOWN IN FIG. 4, AFTER INITIAL MEPYRAMINE MALEATE TREATMENT, URTICARIAL LESIONS WERE DISAPPEARED IN THE HORSE ABOVE.
designed to show both extent and severity of the disease and to monitor therapy. Comparison of the two groups revealed that the clinical scores did not differ between the groups on hour 0, while the treatment group showed a significantly lower clinical score than placebo group on hours 6 and 12 (P<0.05) to hours 18 and 24 (P<0.001).

CONCLUSION

Treatment with mepyramine maleate resulted in a statistically significant cure on urticaria affected horses and the clinical signs resolved in every case treated. On the basis of clinical examinations, mepyramine maleate was not associated with any adverse effect. Further studies with larger numbers of horses control groups are required. It should be mentioned that urticarial diseases show minor unsignificant clinical signs to systemic life-threatening condition, therefore if the underlying condition is not defined and a definitive diagnosis cannot be warranted, mepyramine maleate should be the choice of medication, at least in an attempt to manage the clinical signs.

BIBLIOGRAPHIC REFERENCES